While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW Mulls “Ultra-Orphan” Drug System; Designation Might Become Possible with Pre-Clinical, Healthy Subject Data
July 22, 2013
-
REGULATORY US Aims for Lifting of Ban on Mixed Care: Prof. Murakami of Yamagata University
July 22, 2013
-
ORGANIZATION FPMAJ Settles on Industry View for TPP, Demands Intellectual Property Protection on Par with Japanese Rules
July 19, 2013
-
REGULATORY South Korean MOHW Officials Announce Roadmap for South Korea to Become No. 7 Worldwide in New Drug Development by 2020
July 19, 2013
-
BUSINESS Pfizer Paid 23.9 Billion Yen to Physicians, Medical Institutions in FY2012; 1st Disclosure under JPMA Guidelines
July 18, 2013
-
ACADEMIA University’s Seriousness to Unravel Diovan Saga Called into Question
July 17, 2013
-
REGULATORY 2nd Committee on Drugs to Discuss Approval for Asthma Treatment Flutiform on July 26
July 17, 2013
-
REGULATORY MHLW, US FDA to Exchange Information with a View to Standardizing Review Guidelines for Regenerative Medicines
July 17, 2013
-
REGULATORY Health Ministry to Set Up Committee on Diovan Studies, Compile Preventive Measures for Clinical Data Manipulation
July 16, 2013
-
REGULATORY MHLW Presses Kyoto Prefectural University of Medicine to Carry on Diovan Probe
July 16, 2013
-
ACADEMIA “Data Manipulated” in KYOTO Heart Study: Univ. Probe
July 12, 2013
-
ORGANIZATION JPWA Sets Up New Committee on Consumption Tax, NHI Drug Pricing Issues
July 12, 2013
-
BUSINESS Drug Makers to Disclose Payment Information This Summer Based on Transparency Guidelines
July 11, 2013
-
BUSINESS Blood Derivative Titan CSL Set to Beef Up Japan Biz with New Products
July 10, 2013
-
REGULATORY TPP Member States to Brief Japan on Drug Pricing, Intellectual Property on July 25
July 9, 2013
-
ORGANIZATION JSGM Officially Announces Unified Brand Name Plan for Generic Combination Drugs; 1st Single Name to Be Given to Preminent
July 8, 2013
-
ORGANIZATION JSGM Working to Build Consensus on Unified Brand Names for Generic Combination Drugs
July 5, 2013
-
ACADEMIA “No Data Manipulation” in VART Study of Diovan: Interim Report of Japanese Society of Hypertension
July 4, 2013
-
REGULATORY Notification Calls for Simultaneous Filing of Applications for Companion Diagnostics and Drugs
July 3, 2013
-
BUSINESS Japanese Society of Chemotherapy Joins Hands with Pharmas, Govt to Spur New Antibiotic Development
July 2, 2013
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…